Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved amivantamab and hyaluronidase-lpuj, marketed as Rybrevant Faspro, for subcutaneous injection across all indications approved for intravenous amivantamab.
The approval is primarily a delivery-route change, but route matters in oncology operations because infusion time, chair capacity and patient burden affect access.
Subcutaneous versions can make established therapies easier to deliver if safety, dosing and workflow are managed well.
Why It Matters
Formulation changes can meaningfully alter cancer-care logistics even when the target biology is unchanged.
What to Watch
Watch clinic adoption, payer rules and whether subcutaneous delivery reduces treatment burden.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDADrug DeliveryLung CancerOncology